Two-Week Heart Monitor Doubles Detection of Dangerous Arrhythmias After Fainting
- Fitting a wearable heart monitor for 14 days when patients visit emergency departments with unexplained fainting more than doubles the detection rate of life-threatening heart rhythm problems, according...
- Around 650,000 people visit emergency rooms with unexplained fainting each year in the UK.
- While many fainting episodes are harmless, they can signal dangerous arrhythmias.
Fitting a wearable heart monitor for 14 days when patients visit emergency departments with unexplained fainting more than doubles the detection rate of life-threatening heart rhythm problems, according to a study led by the University of Edinburgh.
A 14-Day Monitor Doubles Arrhythmia Detection Rates
Around 650,000 people visit emergency rooms with unexplained fainting each year in the UK.
While many fainting episodes are harmless, they can signal dangerous arrhythmias. These abnormal heart rhythms are notoriously difficult to diagnose because patients usually recover by the time they reach the hospital, meaning standard tests often show normal results.
The Bottleneck of Standard Outpatient Care
Standard care typically involves referring patients for a Holter monitor, a small device worn for just 48 hours.
Because of outpatient clinic backlogs, patients often wait anywhere from six weeks to two years after an emergency department visit to receive a monitor, creating a wide window where hidden cardiac issues can go unnoticed.
The University of Edinburgh-led research team evaluated 2,234 people who arrived at UK emergency departments with unexplained fainting. Half of the volunteers received the new two-week chest monitor, while the other half received standard care, according to study findings.
Continuous Tracking Outpaces Traditional Timelines
Measuring heart rhythm continuously over a two-week period dramatically changes diagnostic timelines.
According to researchers, the new strategy identified heart rhythm problems in 22 percent of the monitoring group after one year, compared with just nine percent of patients who received standard care.
The study showed that arrhythmias were identified in an average of 22 days for patients wearing the chest monitor, down from 54.5 days under standard care protocols. Clinicians received continuous data and were alerted within 24 working hours if the device picked up a serious arrhythmia.
Faster Intervention and Key Device Metrics
Quicker detection led to faster medical intervention.
Among the monitoring group, 10.8 percent received anti-arrhythmic medication and 6.8 percent had a pacemaker implanted. In comparison, 7.3 percent of the standard care group received medication and 4.6 percent received a pacemaker.
Identified conditions included life-threatening issues such as complete heart block and heart pauses lasting longer than six seconds. The chest-worn device itself is small, roughly the size of a car key fob, and is worn in the middle of the chest to allow continuous recording.
Mortality Drop Points to Potential NHS Shift
The trial revealed a significant difference in one-year mortality rates between the two groups.
The death rate after one year in the two-week monitoring group stood at 1.5 percent, which is almost half the 2.9 percent rate recorded in the standard care group.
Researchers noted that this reduction in mortality provides strong evidence that continuous two-week monitoring can save lives. Experts hope the strategy will be adopted across the NHS to prevent patients with hidden cardiac conditions from slipping through the net.